Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

771 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L; NIAID HIV Vaccine Trials Network. Spearman P, et al. Among authors: haynes bf. Vaccine. 2009 Jan 7;27(2):243-9. doi: 10.1016/j.vaccine.2008.10.051. Epub 2008 Nov 7. Vaccine. 2009. PMID: 18996425 Free PMC article. Clinical Trial.
Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy.
Markert ML, Alvarez-McLeod AP, Sempowski GD, Hale LP, Horvatinovich JM, Weinhold KJ, Bartlett JA, D'Amico TA, Haynes BF. Markert ML, et al. Among authors: haynes bf. AIDS Res Hum Retroviruses. 2001 Nov 20;17(17):1635-43. doi: 10.1089/088922201753342040. AIDS Res Hum Retroviruses. 2001. PMID: 11779351
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.
Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, Moody MA, Ferrari G, Weinhold KJ, Miller SE, Reich CF 3rd, Qin L, Self SG, Shaw GM, Denny TN, Jones LE, Pisetsky DS, Haynes BF. Gasper-Smith N, et al. Among authors: haynes bf. J Virol. 2008 Aug;82(15):7700-10. doi: 10.1128/JVI.00605-08. Epub 2008 May 28. J Virol. 2008. PMID: 18508902 Free PMC article.
Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.
Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE, Liao HX, Kepler TB, Haynes BF, Ramsburg E. Barefoot B, et al. Among authors: haynes bf. Vaccine. 2008 Nov 11;26(48):6108-18. doi: 10.1016/j.vaccine.2008.09.007. Epub 2008 Sep 20. Vaccine. 2008. PMID: 18809447 Free PMC article.
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.
Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ, Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD. Freel SA, et al. Among authors: haynes bf. J Virol. 2010 May;84(10):4998-5006. doi: 10.1128/JVI.00138-10. Epub 2010 Mar 3. J Virol. 2010. PMID: 20200250 Free PMC article.
771 results